Back to Search Start Over

Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia.

Authors :
Hock BD
Fernyhough LJ
Gough SM
Steinkasserer A
Cox AG
McKenzie JL
Source :
Leukemia research [Leuk Res] 2009 Aug; Vol. 33 (8), pp. 1089-95. Date of Electronic Publication: 2009 Feb 04.
Publication Year :
2009

Abstract

Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P=0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb+IL-4 significantly increases sCD83 release (23-117-fold, P=0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release (P=0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression.

Details

Language :
English
ISSN :
1873-5835
Volume :
33
Issue :
8
Database :
MEDLINE
Journal :
Leukemia research
Publication Type :
Academic Journal
Accession number :
19195701
Full Text :
https://doi.org/10.1016/j.leukres.2009.01.001